Background
Methods
Data source and population
Code lists
Patients
Variables
Exposure
Outcomes
Covariables
Follow-up
Statistical analyses
Main analyses
Missing covariable data
Exposed (n = 70,476) | Unexposed (n = 70,476) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
AKI | Count | % | Missing (%) | Count | % | Missing (%) | ||||
AKI | 586 | 0.8 | 0.0 | 348 | 0.5 | 0.0 | ||||
No AKI | 69,890 | 99.2 | 0.0 | 70,128 | 99.5 | 0.0 | ||||
Gender | Male (%) | Female (%) | Missing (%) | Male (%) | Female (%) | Missing (%) | ||||
AKI | 358 (61.1) | 228 (38.9) | 0.0 | 202 (58.1) | 146 (42.0) | 0.0 | ||||
No AKI | 38,007 (54.4) | 31,883 (45.6) | 0.0 | 38,163 (54.4) | 31,965 (45.6) | 0.0 | ||||
Age at Exposure | < 65 (%) | 65–74 (%) | > = 75 (%) | Missing (%) | < 65 (%) | 65–74 (%) | > = 75 (%) | Missing (%) | ||
AKI | 229 (39.1) | 179 (30.6) | 178 (30.4) | 0.0 | 137 (39.4) | 108 (31.0) | 103 (29.6) | 0.0 | ||
No AKI | 37,096 (53.1) | 19,409 (27.8) | 13,385 (19.2) | 0.0 | 36,589 (52.2) | 20,331 (29.0) | 13,208 (18.8) | 0.0 | ||
Diagnosis to Exposure | < 30 days (%) | 30–179 (%) | 180–364 (%) | > = 365 (%) | Missing (%) | < 30 days (%) | 30–179 (%) | 180–364 (%) | > = 365 (%) | Missing (%) |
AKI | 191 (32.6) | 83 (14.2) | 42 (7.2) | 270 (46.1) | 0.0 | 39 (11.3) | 115 (33.2) | 35 (10.1) | 157 (45.4) | 0.0 |
No AKI | 26,347 (37.7) | 8880 (12.7) | 4015 (5.7) | 30,648 (43.9) | 0.0 | 7203 (10.3) | 25,894 (36.9) | 5736 (8.2) | 31,297 (44.6) | 0.0 |
# Medications | 1 (%) | > = 2 (%) | Missing (%) | 1 (%) | > = 2 (%) | Missing (%) | ||||
AKI | 256 (43.7) | 330 (56.3) | 0.0 | 297 (85.8) | 49 (14.2) | 0.0 | ||||
No AKI | 34,803 (49.8) | 35,087 (50.2) | 0.0 | 60,292 (86.0) | 9838 (14.0) | 0.0 | ||||
# GP Consultation | < 10 (%) | 10–19 (%) | 20–29 (%) | > = 30 (%) | Missing (%) | < 10 (%) | 10–19 (%) | 20–29 (%) | > = 30 (%) | Missing (%) |
AKI | 142 (24.2) | 192 (32.8) | 126 (21.5) | 126 (21.5) | 0.0 | 72 (20.7) | 123 (35.3) | 74 (21.3) | 79 (22.7) | 0.0 |
No AKI | 20,781 (29.7) | 24,887 (35.6) | 12,814 (18.3) | 11,408 (16.3) | 0.0 | 18,615 (26.5) | 26,116 (37.2) | 13,457 (19.2) | 11,940 (17.0) | 0.0 |
Systolic Blood Pressure | < 120 (%) | 120–139 (%) | 140–159 (%) | > = 160 (%) | Missing (%) | < 120 (%) | 120–139 (%) | 140–159 (%) | > = 160 (%) | Missing (%) |
AKI | 30 (5.5) | 139 (25.4) | 226 (41.2) | 153 (27.9) | 6.5 | 25 (7.3) | 131 (38.3) | 150 (43.9) | 36 (10.5) | 1.7 |
No AKI | 2089 (3.2) | 13,458 (20.8) | 30,641 (47.3) | 18,637 (28.8) | 7.2 | 5202 (7.7) | 24,012 (35.6) | 28,854 (42.7) | 9479 (14.0) | 3.7 |
Smoking | Yes (%) | No (%) | Ex (%) | Missing (%) | Yes (%) | No (%) | Ex (%) | Missing (%) | ||
AKI | 115 (19.8) | 247 (42.5) | 219 (37.7) | 71 (20.4) | 156 (44.8) | 121 (34.8) | 0.0 | |||
No AKI | 12,260 (17.6) | 34,823 (50.1) | 22,487 (32.3) | 12,104 (17.3) | 35,521 (50.8) | 22,364 (32.0) | 0.2 | |||
GFR | > = 60 (%) | 45–59 (%) | < 45 (%) | Missing (%) | > = 60 (%) | 45–59 (%) | < 45 (%) | Missing (%) | ||
AKI | 398 (77.7) | 81 (15.8) | 33 (6.5) | 239 (76.1) | 55 (17.5) | 20 (6.4) | 9.8 | |||
No AKI | 42,103 (85.8) | 5883 (12.0) | 1070 (2.2) | 38,014 (84.9) | 6090 (13.6) | 678 (1.5) | 36.1 | |||
# Chronic Conditions | 1 (%) | > = 2 (%) | Missing (%) | 1 (%) | > = 2 (%) | Missing (%) | ||||
AKI | 417 (71.2) | 169 (28.8) | 285 (82.4) | 61 (17.6) | 0.0 | |||||
No AKI | 56,163 (80.4) | 13,727 (19.6) | 61,945 (88.3) | 8185 (11.7) | 0.0 |
Sensitivity analyses
Results
Descriptive information
Exposed (n = 70,476) | Unexposed (n = 70,476) | |||||||
---|---|---|---|---|---|---|---|---|
Overall | Rate (95% CI)1 | Rate (95% CI) | ||||||
2.54 (2.34–2.76) | 1.7 (1.53–1.89) | |||||||
Gender | Male | Female | Male | Female | ||||
2.84 (2.56–3.15) | 2.18 (1.91–2.48) | 1.8 (1.57–2.07) | 1.57 (1.33–1.84) | |||||
Age at Exposure | < 65 | 65–74 | > = 75 | < 65 | 65–74 | > = 75 | ||
1.82 (1.6–2.08) | 2.8 (2.41–3.24) | 4.35 (3.75–5.03) | 1.22 (1.03–1.45) | 1.82 (1.51–2.2) | 2.99 (2.46–3.563) | |||
Diagnosis to Exposure | < 30 days | 30–179 | 180–364 | > = 365 | < 30 days | 30–179 | 180–364 | > = 365 |
2.24 (1.95–2.59) | 3.04 (2.45–3.77) | 3.26 (2.41–4.41) | 2.56 (2.28–2.89) | 2.21 (1.62–3.03) | 1.54 (1.28–1.84) | 2.14 (1.54–2.98) | 1.65 (1.41–1.93) | |
# Medications | 1 | > = 2 | 1 | > = 2 | ||||
2.14 (1.89–2.42) | 2.98 (2.67–3.31) | 1.71 (1.53–1.92) | 1.61 (1.22–2.13) | |||||
# GP Consultation | < 10 | 10–19 | 20–29 | > = 30 | < 10 | 10–19 | 20–29 | > = 30 |
1.9 (1.61–2.24) | 2.31 (2–2.66) | 3.12 (2.62–3.72) | 3.9 (3.27–4.64) | 1.18 (0.93–1.49) | 1.57 (1.32–1.88) | 2.01 (1.6–2.52) | 2.71 (2.17–3.37) | |
Systolic Blood Pressure | < 120 | 120–139 | 140–159 | > = 160 | < 120 | 120–139 | 140–159 | > = 160 |
4.66 | 3.18 | 2.19 | 2.19 | 1.37 | 1.77 | 1.73 | 1.34 | |
Smoking | Yes | No | Ex | Yes (%) | No (%) | Ex (%) | ||
2.63 | 2.05 | 3.01 | 2.09 | 1.49 | 1.73 | |||
GFR | > = 60 | 45–59 | < 45 | > = 60 | 45–59 | < 45 | ||
2.3 | 2.6 | 7.41 | 1.54 | 1.92 | 5.33 | |||
# Chronic Conditions | 1 | > = 2 | 1 | > = 2 | ||||
2.27 (2.06–2.50) | 3.61 (3.10–4.19) | 1.58 (1.40–1.77) | 2.64 (2.06–3.40) |
Association between exposure to RAAS inhibitors/ diuretics and acute kidney injury
Main analyses
Model | Covariables | HR (AKI) | 95% LCI | 95% UCI |
---|---|---|---|---|
Baseline1 | Unexposed | 1 | ||
Exposed | 1.48 | 1.3 | 1.7 | |
Baseline + Sex | Unexposed | 1 | ||
Exposed | 1.48 | 1.3 | 1.7 | |
Male | 1 | |||
Female | 0.81 | 0.71 | 0.92 | |
Baseline + Age | Unexposed | 1 | ||
Exposed | 1.48 | 1.29 | 1.69 | |
< 65 years | 1 | |||
65–74 | 1.53 | 1.31 | 1.79 | |
> = 75 | 2.46 | 2.11 | 2.88 | |
Baseline + Chronic Time | Unexposed | 1 | ||
Exposed | 1.53 | 1.33 | 1.77 | |
< 30 days | 1 | |||
30–179 days | 1.1 | 0.89 | 1.35 | |
180–364 days | 1.37 | 1.05 | 1.78 | |
> = 365 days | 1.05 | 0.89 | 1.24 | |
Baseline + CKD | Unexposed | 1 | ||
Exposed | 1.5 | 1.32 | 1.72 | |
No CKD | 1 | |||
CKD | 1.93 | 1.63 | 2.27 | |
Baseline + DM | Unexposed | 1 | ||
Exposed | 1.41 | 1.24 | 1.61 | |
No DM | 1 | |||
DM | 1.89 | 1.61 | 2.21 | |
Baseline + HF | Unexposed | 1 | ||
Exposed | 1.41 | 1.23 | 1.61 | |
No HF | 1 | |||
HF | 3.65 | 2.74 | 4.86 | |
Baseline + HT | Unexposed | 1 | ||
Exposed | 1.59 | 1.39 | 1.82 | |
No HT | 1 | |||
HT | 0.53 | 0.47 | 0.61 | |
Baseline + IHD | Unexposed | 1 | ||
Exposed | 1.5 | 1.31 | 1.71 | |
No IHD | 1 | |||
IHD | 1.17 | 1 | 1.37 | |
Baseline + Medications | Unexposed | 1 | ||
Exposed | 1.37 | 1.19 | 1.58 | |
1 | 1 | |||
> = 2 | 1.27 | 1.11 | 1.46 | |
Baseline + GP Consultations | Unexposed | 1 | ||
Exposed | 1.5 | 1.31 | 1.71 | |
< 10 | 1 | |||
10–19 | 1.27 | 1.07 | 1.51 | |
20–29 | 1.71 | 1.41 | 2.07 | |
> = 30 | 2.23 | 1.84 | 2.71 | |
Baseline + SBP | Unexposed | 1 | ||
Exposed | 1.59 | 1.38 | 1.83 | |
< 120 | 1 | |||
120–139 | 0.88 | 0.65 | 1.17 | |
140–159 | 0.71 | 0.53 | 0.94 | |
> = 160 | 0.68 | 0.5 | 0.92 | |
Baseline + Smoking | Unexposed | 1 | ||
Exposed | 1.48 | 1.3 | 1.69 | |
No | 1 | |||
Yes | 1.35 | 1.13 | 1.6 | |
Ex | 1.34 | 1.16 | 1.54 | |
Baseline + GFR | Unexposed | 1 | ||
Exposed | 1.47 | 1.29 | 1.68 | |
> = 60 | 1 | |||
45–59 | 1.29 | 1.07 | 1.55 | |
< 45 | 2.92 | 2.2 | 3.88 | |
Full Model | Unexposed | 1 | ||
Exposed | 1.23 | 1.04 | 1.45 | |
Full Model (inc meds*exposure) | 1 (exposed) | 1.1 | 0.91 | 1.33 |
> = 2 (exposed) | 1.49 | 1.06 | 2.11 |
Model | Covariates | HR (AKI) | 95% LCI | 95% UCI |
---|---|---|---|---|
Baseline | Unexposed | 1 | ||
Exposed | 1.48 | 1.3 | 1.7 | |
Baseline + P-Score (Full Model) | Unexposed | 1 | ||
Exposed | 1.24 | 1.05 | 1.47 | |
Full Model (inc meds*exposure) | 1 (exposed) | 1.09 | 0.89 | 1.33 |
> = 2 (exposed) | 1.61 | 1.14 | 2.28 |